Emerging studies suggest Retatrutide , a dual agonist targeting both the gut-brain axis and GIP , could represent a promising step forward for weight loss . Preliminary patient investigations have https://getretatrutideaustralia.com/blog/retatrutide-vs-tirzepatide-semaglutide